BriaCell
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bellevue Centre 235 -15th St Ste 300, Va...Phone Number
(604) 921-1810Website
www.briacell.comRevenue
-Stock Symbol
BCTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About BriaCell
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Explore more
BriaCell Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BriaCell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
BriaCell, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BriaCell launches new products
Earning: See what the market has to say on BriaCell recently announced quarterly report
Funding: Get notified immidiatlly once BriaCell has new funding data
Congratulate Masked Content for being promoted to Masked Content at BriaCell
Click to see if BriaCell had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if BriaCell is spiking on competitors!
Check if BriaCell has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at BriaCell
Find more new buyers
Compare Similar Companies to BriaCell
Compare insights from companies similar to BriaCell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BriaCell is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BriaCell is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BriaCell.
BriaCell financials insights
Gather financial insights about BriaCell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$265K
2021
Stock Offering
$59.5M
2023
Share Placement
$4M
2024
Share Placement
$5M
BriaCell Tech Stack
A closer look at the technologies used by BriaCell
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Partnership
Project
Partnership, Product Development, Research & Development, Business Development, Medical Research, Clinical Operations
Earnings
Product Management
BriaCell News & Media
BriaCell Presents Positive Clinical Data at ASCO 2026
2026 ASCO Annual Meeting, May 29-June 2, 2026, at McCormick Place, Chicago, IllinoisBriaCell Therapeutics Announces Pricing of Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the CoBriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checBriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce positive clinical data from three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29–June 2, 2026 at McCormick Place, Chicago, Illinoi
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BriaCell
Sign Up For FreeTo access detailed company insights
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for b... Read More
